Literature DB >> 18729812

Aging, stem cells, and mammalian target of rapamycin: a prospect of pharmacologic rejuvenation of aging stem cells.

Mikhail V Blagosklonny1.   

Abstract

What is the relationship between stem cell aging and organismal aging? Does stem cell aging cause organismal aging or vice versa? Will stem cell aging aggravate age-related diseases? And what is stem cell aging? As suggested herein, hyperstimulation of signal transduction pathways can render cells compensatorily irresponsive. And the hallmark of stem cell aging is poor responsiveness to activating stimuli. On the basis of the hypothesis that insensitivity to stimuli is in part due to hyperactivation of the target of rapamycin (TOR), this article suggests a means of pharmacologic rejuvenation of stem cells and wound-healing cells.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18729812     DOI： 10.1089/rej.2008.0722

Source DB:  PubMed          Journal:  Rejuvenation Res        ISSN： 1549-1684            Impact factor:   4.663


  40 in total

1.  mTOR-mediated activation of p70 S6K induces differentiation of pluripotent human embryonic stem cells.

Authors:  Charles A Easley; Ahmi Ben-Yehudah; Carrie J Redinger; Stacie L Oliver; Sandra T Varum; Vonya M Eisinger; Diane L Carlisle; Peter J Donovan; Gerald P Schatten
Journal:  Cell Reprogram       Date:  2010-06       Impact factor: 1.987

Review 2.  Geroconversion: irreversible step to cellular senescence.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

3.  Enhancing therapeutic efficacy by targeting non-oncogene addicted cells with combinations of signal transduction inhibitors and chemotherapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; William Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-15       Impact factor: 4.534

4.  The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy.

Authors:  Stephen L Abrams; Linda S Steelman; John G Shelton; Ellis W T Wong; William H Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey
Journal:  Cell Cycle       Date:  2010-05-10       Impact factor: 4.534

5.  Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycin.

Authors:  Irina G Popovich; Vladimir N Anisimov; Mark A Zabezhinski; Anna V Semenchenko; Margarita L Tyndyk; Maria N Yurova; Mikhail V Blagosklonny
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

6.  Comparison of rapamycin schedules in mice on high-fat diet.

Authors:  Olga V Leontieva; Geraldine M Paszkiewicz; Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

Review 7.  Cdc42 and aging of hematopoietic stem cells.

Authors:  Hartmut Geiger; Yi Zheng
Journal:  Curr Opin Hematol       Date:  2013-07       Impact factor: 3.284

8.  Quantifying pharmacologic suppression of cellular senescence: prevention of cellular hypertrophy versus preservation of proliferative potential.

Authors:  Zoya N Demidenko; Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-12-31       Impact factor: 5.682

Review 9.  Validation of anti-aging drugs by treating age-related diseases.

Authors:  Mikhail V Blagosklonny
Journal:  Aging (Albany NY)       Date:  2009-03-28       Impact factor: 5.682

Review 10.  Strategies to Enhance the Effectiveness of Adult Stem Cell Therapy for Ischemic Heart Diseases Affecting the Elderly Patients.

Authors:  Roshni Khatiwala; Chuanxi Cai
Journal:  Stem Cell Rev Rep       Date:  2016-04       Impact factor: 5.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.